Your browser doesn't support javascript.
loading
Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction.
Vukicevic, Slobodan; Colliva, Andrea; Kufner, Vera; Martinelli, Valentina; Moimas, Silvia; Vodret, Simone; Rumenovic, Viktorija; Milosevic, Milan; Brkljacic, Boris; Delic-Brkljacic, Diana; Correa, Ricardo; Giacca, Mauro; Maglione, Manuel; Bordukalo-Niksic, Tatjana; Dumic-Cule, Ivo; Zacchigna, Serena.
Afiliação
  • Vukicevic S; Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Colliva A; Cardiovascular Biology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
  • Kufner V; Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • Martinelli V; Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Moimas S; Molecular Medicine, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
  • Vodret S; Molecular Medicine, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
  • Rumenovic V; Cardiovascular Biology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
  • Milosevic M; Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Brkljacic B; Department for Environmental Health and Occupational and Sports Medicine, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Delic-Brkljacic D; Department of Diagnostic and Interventional Radiology, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Correa R; Department of Cardiology, Clinical Hospital Sisters of Mercy, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Giacca M; Cardiovascular Biology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
  • Maglione M; Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • Bordukalo-Niksic T; Molecular Medicine, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
  • Dumic-Cule I; School of Cardiovascular Medicine & Sciences, King's College London, London, UK.
  • Zacchigna S; Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Nat Commun ; 13(1): 81, 2022 01 10.
Article em En | MEDLINE | ID: mdl-35013172

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiotônicos / Cicatriz / Fibrose Endomiocárdica / Proteína Morfogenética Óssea 1 / Anticorpos Monoclonais / Infarto do Miocárdio Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiotônicos / Cicatriz / Fibrose Endomiocárdica / Proteína Morfogenética Óssea 1 / Anticorpos Monoclonais / Infarto do Miocárdio Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article